BLFS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 573.62 -- higher than 93.82% of US-listed equities with positive expected earnings growth.
Price to trailing twelve month operating cash flow for BLFS is currently 185.23, higher than 98.02% of US stocks with positive operating cash flow.
BLFS's price/sales ratio is 25.16; that's higher than the P/S ratio of 93.51% of US stocks.
Stocks that are quantitatively similar to BLFS, based on their financial statements, market capitalization, and price volatility, are LLNW, XXII, EPAY, PD, and CNTG.
BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company was founded in 1987 and is based in Bothell, Washington.
BLFS Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Biolife Solutions Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Biolife Solutions Inc ranked in the 12th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 88.17%. As for the metrics that stood out in our discounted cash flow analysis of Biolife Solutions Inc, consider:
Interest coverage, a measure of earnings relative to interest payments, is -1,238.5; that's higher than just 1.46% of US stocks in the Healthcare sector that have positive free cash flow.
The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 2.14% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
LGND, RGEN, QGEN, TEVA, and ELAN can be thought of as valuation peers to BLFS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Strategy requires thought, tactics require observation. – Max Euwe Despite the technological advancement in almost every industry, this pandemic has opened our eyes to the medical field's substantial deficiencies. Funding for innovative treatments and drug discovery are now deemed necessary while these were being debated upon pre-pandemic. This development in...
Michael A. Gayed, CFA on Seeking Alpha | September 28, 2020
BioLife Solutions ([[BLFS]] +5.2%) initiated at Cowen with Outperform, PT $33, indicating the stock is significantly undervalued; currently hovering around 52-week high levels gained 166% in past 6 months trading.Wall Street Analysts Rating is Very Bullish, PT $25.36 has been crossed already by the company.Analyst Chris said that the company is...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...